Extensive-stage small-cell lung cancer: first-line and second-line treatment options
J Zugazagoitia, L Paz-Ares - Journal of Clinical Oncology, 2022 - ascopubs.org
Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …
than two decades without clinical progress, the addition of programmed cell death protein 1 …
Small-cell lung cancer
The incidence and mortality of small-cell lung cancer worldwide make this disease a notable
health-care issue. Diagnosis relies on histology, with the use of immunohistochemical …
health-care issue. Diagnosis relies on histology, with the use of immunohistochemical …
Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung
Cancer (SCLC) provide recommended management for patients with SCLC, including …
Cancer (SCLC) provide recommended management for patients with SCLC, including …
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer
J von Pawel, R Jotte, DR Spigel… - Journal of clinical …, 2014 - ascopubs.org
Purpose Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor,
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …
Small cell lung cancer
Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈ 15%) are
small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for …
small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for …
Treatment of small cell lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines
JR Jett, SE Schild, KA Kesler, GP Kalemkerian - Chest, 2013 - Elsevier
Background Small cell lung cancer (SCLC) is a lethal disease for which there have been
only small advances in diagnosis and treatment in the past decade. Our goal was to revise …
only small advances in diagnosis and treatment in the past decade. Our goal was to revise …
Treatment advances in small cell lung cancer (SCLC)
SN Waqar, D Morgensztern - Pharmacology & therapeutics, 2017 - Elsevier
Small cell lung cancer (SCLC) is an aggressive tumor characterized by rapid doubling time
and high propensity for early development of disseminated disease. Although most patients …
and high propensity for early development of disseminated disease. Although most patients …
Berzosertib plus topotecan vs topotecan alone in patients with relapsed small cell lung cancer: a randomized clinical trial
N Takahashi, Z Hao, LC Villaruz, J Zhang, J Ruiz… - JAMA …, 2023 - jamanetwork.com
Importance Patients with relapsed small cell lung cancer (SCLC), a high replication stress
tumor, have poor prognoses and few therapeutic options. A phase 2 study showed antitumor …
tumor, have poor prognoses and few therapeutic options. A phase 2 study showed antitumor …
Therapy of small cell lung cancer (SCLC) with a topoisomerase-i–inhibiting antibody–drug conjugate (ADC) targeting trop-2, sacituzumab govitecan
JE Gray, RS Heist, AN Starodub, DR Camidge… - Clinical Cancer …, 2017 - AACR
Abstract Purpose: We evaluated a Trop-2–targeting antibody conjugated with SN-38 in
metastatic small cell lung cancer (mSCLC) patients. Experimental Design: Sacituzumab …
metastatic small cell lung cancer (mSCLC) patients. Experimental Design: Sacituzumab …
[HTML][HTML] Chemotherapy advances in small-cell lung cancer
BA Chan, JIG Coward - Journal of thoracic disease, 2013 - ncbi.nlm.nih.gov
Although chemotherapeutic advances have recently been heralded in lung
adenocarcinomas, such success with small-cell lung cancer (SCLC) has been ominously …
adenocarcinomas, such success with small-cell lung cancer (SCLC) has been ominously …